In vivo formation of β-oxidized metabolites of leukotriene E4 in the rat

P. Perrin; J. Zirrolli; D. O. Stene; J. P. Lellouche; J. P. Beaucourt; R. C. Murphy

doi:10.1016/0090-6980(89)90031-2

In vivo formation of β-oxidized metabolites of leukotriene E₄ in the rat

P. Perrin
, J. Zirrolli
, D. O. Stene
, J. P. Lellouche
, J. P. Beaucourt
, R. C. Murphy

University of Colorado Anschutz Medical Campus
Serv. des Molecules Marquees

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

Intraperitoneal administration of [³H]-leukotriene E₄ in the rat resulted in the appearance of radiolabel in urine and feces. Separation of polar urinary metabolites and chromatographic comparison of synthetic metabolites indicated the in vivo formation of ω-oxidized metabolites of LTE₄ with sequential β-oxidation. Futhermore, the metabolite identified as 16-carboxy-17,18,19,20-tetranor-14,15-dihydro-N-acetyl-LTE₄ substantiates the biochemical patheway of β-oxidation in vivo involving the 2,4-dienoyl CoA reductase as an integral step. These results substantiate β-oxidation of sulfidopeptide leukotrienes in vivo and these metabolites account for some of the major urinary metabolites of this class of lipid mediator.

Original language	English
Pages (from-to)	53-60
Number of pages	8
Journal	Prostaglandins
Volume	37
Issue number	1
DOIs	https://doi.org/10.1016/0090-6980(89)90031-2
State	Published - Jan 1989
Externally published	Yes

Bibliographical note

Funding Information:
This work was supported, in part, by a grant from the National Institutes of Health (HL25785) and the Bourses de l’O.T.A.N., France. The authors wish to thank Dr. Eric Brass for preparation of the isolated hepatocytes used in these studies and Ms. Deborah Beckworth for preparation of this manuscript.

Funding

This work was supported, in part, by a grant from the National Institutes of Health (HL25785) and the Bourses de l’O.T.A.N., France. The authors wish to thank Dr. Eric Brass for preparation of the isolated hepatocytes used in these studies and Ms. Deborah Beckworth for preparation of this manuscript.

Funders	Funder number
National Institutes of Health
National Heart, Lung, and Blood Institute	R37HL025785

Access to Document

10.1016/0090-6980(89)90031-2

Cite this

@article{6bfee509148a4ccfb94aaa9a0e429ba9,

title = "In vivo formation of β-oxidized metabolites of leukotriene E4 in the rat",

abstract = "Intraperitoneal administration of [3H]-leukotriene E4 in the rat resulted in the appearance of radiolabel in urine and feces. Separation of polar urinary metabolites and chromatographic comparison of synthetic metabolites indicated the in vivo formation of ω-oxidized metabolites of LTE4 with sequential β-oxidation. Futhermore, the metabolite identified as 16-carboxy-17,18,19,20-tetranor-14,15-dihydro-N-acetyl-LTE4 substantiates the biochemical patheway of β-oxidation in vivo involving the 2,4-dienoyl CoA reductase as an integral step. These results substantiate β-oxidation of sulfidopeptide leukotrienes in vivo and these metabolites account for some of the major urinary metabolites of this class of lipid mediator.",

author = "P. Perrin and J. Zirrolli and Stene, \{D. O.\} and Lellouche, \{J. P.\} and Beaucourt, \{J. P.\} and Murphy, \{R. C.\}",

note = "Funding Information: This work was supported, in part, by a grant from the National Institutes of Health (HL25785) and the Bourses de l{\textquoteright}O.T.A.N., France. The authors wish to thank Dr. Eric Brass for preparation of the isolated hepatocytes used in these studies and Ms. Deborah Beckworth for preparation of this manuscript.",

year = "1989",

month = jan,

doi = "10.1016/0090-6980(89)90031-2",

language = "אנגלית",

volume = "37",

pages = "53--60",

journal = "Prostaglandins",

issn = "0090-6980",

publisher = "Elsevier B.V.",

number = "1",

}

TY - JOUR

T1 - In vivo formation of β-oxidized metabolites of leukotriene E4 in the rat

AU - Perrin, P.

AU - Zirrolli, J.

AU - Stene, D. O.

AU - Lellouche, J. P.

AU - Beaucourt, J. P.

AU - Murphy, R. C.

N1 - Funding Information: This work was supported, in part, by a grant from the National Institutes of Health (HL25785) and the Bourses de l’O.T.A.N., France. The authors wish to thank Dr. Eric Brass for preparation of the isolated hepatocytes used in these studies and Ms. Deborah Beckworth for preparation of this manuscript.

PY - 1989/1

Y1 - 1989/1

N2 - Intraperitoneal administration of [3H]-leukotriene E4 in the rat resulted in the appearance of radiolabel in urine and feces. Separation of polar urinary metabolites and chromatographic comparison of synthetic metabolites indicated the in vivo formation of ω-oxidized metabolites of LTE4 with sequential β-oxidation. Futhermore, the metabolite identified as 16-carboxy-17,18,19,20-tetranor-14,15-dihydro-N-acetyl-LTE4 substantiates the biochemical patheway of β-oxidation in vivo involving the 2,4-dienoyl CoA reductase as an integral step. These results substantiate β-oxidation of sulfidopeptide leukotrienes in vivo and these metabolites account for some of the major urinary metabolites of this class of lipid mediator.

AB - Intraperitoneal administration of [3H]-leukotriene E4 in the rat resulted in the appearance of radiolabel in urine and feces. Separation of polar urinary metabolites and chromatographic comparison of synthetic metabolites indicated the in vivo formation of ω-oxidized metabolites of LTE4 with sequential β-oxidation. Futhermore, the metabolite identified as 16-carboxy-17,18,19,20-tetranor-14,15-dihydro-N-acetyl-LTE4 substantiates the biochemical patheway of β-oxidation in vivo involving the 2,4-dienoyl CoA reductase as an integral step. These results substantiate β-oxidation of sulfidopeptide leukotrienes in vivo and these metabolites account for some of the major urinary metabolites of this class of lipid mediator.

UR - https://www.scopus.com/pages/publications/0024601073

U2 - 10.1016/0090-6980(89)90031-2

DO - 10.1016/0090-6980(89)90031-2

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 2541469

AN - SCOPUS:0024601073

SN - 0090-6980

VL - 37

SP - 53

EP - 60

JO - Prostaglandins

JF - Prostaglandins

IS - 1

ER -